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ABSTRACT
Objective To identify factors associated with sight- 
threatening diabetic macular oedema (STDM) in Indigenous 
Australians attending an Indigenous primary care clinic in 
remote Australia.
Methods and analysis A cross- sectional study design of 
retinopathy screening data and routinely- collected clinical data 
among 236 adult Indigenous participants with type 2 diabetes 
(35.6% men) set in one Indigenous primary care clinic in 
remote Australia. The primary outcome variable was STDM 
assessed from retinal images.
Results Age (median (range)) was 48 (21–86) years, and 
known diabetes duration (median (range)) was 8.0 (0–24) 
years. Prevalence of STDM was high (14.8%) and similar in 
men and women. STDM was associated with longer diabetes 
duration (11.7 vs 7.9 years, respectively; p<0.001) and 
markers of renal impairment: abnormal estimated Glomerular 
Filtration Rate (eGFR) (62.9 vs 38.3%, respectively; p=0.007), 
severe macroalbuminuria (>300 mg/mmol) (20.6 vs 5.7%, 
respectively; p=0.014) and chronic kidney disease (25.7 vs 
12.2%, respectively; p=0.035). Some clinical factors differed 
by sex: anaemia was more prevalent in women. A higher 
proportion of men were smokers, prescribed statins and had 
increased albuminuria. Men had higher blood pressure, but 
lower glycated Haemoglobin A1c (HbA1c) levels and body 
mass index, than women.
Conclusion STDM prevalence was high and similar in men 
and women. Markers of renal impairment and longer diabetes 
duration were associated with STDM in this Indigenous 
primary care population. Embedded teleretinal screening, 
known diabetes duration- based risk stratification and targeted 
interventions may lower the prevalence of STDM in remote 
Indigenous primary care services.
Trial registration number Australia and New Zealand 
Clinical Trials Register: ACTRN 12616000370404.
INTRODUCTION
The burden of diabetes continues to 
rise globally,1 causes a substantial reduc-
tion in disability- free life expectancy2 and 
Key messages
What is already known about this subject?
 ► Vision loss in diabetes is mainly due to maculopathy. 
The prevalence of diabetic maculopathy is higher 
and diabetic eye screening coverage is lower among 
Indigenous than non- Indigenous Australians.
What are the new findings?
 ► Primary care associations with sight- threatening di-
abetic macular oedema (STDM) among people with 
type 2 diabetes routinely attending a geographically 
remote clinic were assessed for the first time. The 
group with STDM had a longer duration of known di-
abetes, and a higher proportion of those with STDM 
had markers of renal dysfunction and chronic kidney 
disease. Importantly, STDM was present in some 
with newly diagnosed diabetes.
How might these results change the focus of 
research or clinical practice?
 ► There is a need for earlier and targeted primary 
care interventions, such as teleretinal diabetes eye 
screening and risk stratification by diabetes dura-
tion and renal dysfunction to reduce progression to 
STDM. Primary healthcare services require greater 
resources to better support timely eye screening 
and risk- stratification strategies among Indigenous 
Australians living with diabetes in remote Australia.
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disproportionately affects Indigenous Australians, who 
have a fourfold higher prevalence of diabetes3 4 and a three-
fold higher prevalence of vision loss than non- Indigenous 
Australians.5 Sight- threatening diabetic macular oedema 
(STDM) is now a more common cause of vision loss in 
diabetes than proliferative diabetic retinopathy (PDR),6 
and both have been shown to predict cardiovascular 
disease (CVD),7 renal disease and mortality. If timely, 
the frontline ocular treatments of intravitreal injections 
and/or laser for STDM are highly effective8 and vision 
outcomes are similar in Indigenous and non- Indigenous 
Australians.9 However, recent national data confirm the 
prevalence of STDM remains higher among Indigenous 
than non- Indigenous Australians (6.0 vs 3.8%),10 higher 
than has been reported in a review of previous Indige-
nous Australian diabetes studies11 and much higher 
than in some Indigenous populations, such as American 
Indians and Alaskan Natives in whom reported STDM 
prevalence was 0.9%.12
In predominantly non- Indigenous adults with type 
2 diabetes (T2D), once- daily oral fenofibrate has been 
shown by the Fenofibrate Intervention and Event 
Lowering in Diabetes (FIELD) and Action to Control 
Cardiovascular Risk in Diabetes (ACCORD) lipid trials 
to significantly reduce the risk of both STDM and 
PDR,13 14 suggesting medical management of diabetic 
retinopathy (DR) with fenofibrate might be a useful 
primary care intervention to attenuate the risk of STDM 
in remote Australia. DR assessment in Australia is largely 
government funded and undertaken by the ophthalmic 
workforce in eye- care clinics or ophthalmic outreach 
services. Increasingly, DR screening of Indigenous 
Australians in non- urban regions occurs as a telemedi-
cine service provided by non- ophthalmic primary care 
clinical staff, trained as retinal imagers and offsite certi-
fied retinal graders.
Until recently, the earliest stages of diabetic macu-
lopathy have been difficult to detect with common DR 
screening technologies, typically non- stereo retinal 
fundus images obtained using non- mydriatic retinal 
cameras. Consequently, more comprehensive documen-
tation of the epidemiology of diabetic maculopathy lags 
that of what is known about DR.15 However, it is estab-
lished that diabetic maculopathy can develop at any stage 
of DR, as STDM can be detected in the absence of other 
extramacular DR, and that the risk of developing STDM 
increases with the severity of DR. While there is evidence 
that (extramacular) retinopathy and maculopathy share 
common risk factors, the epidemiology of maculopathy 
may differ in type 1 (T1D) and T2D, suggesting risk 
profiles for maculopathy may be population specific. For 
example, the risk of maculopathy is greater in (T1D) 
than in T2D for any duration of diabetes greater than 10 
years, while risk of maculopathy is associated with hyper-
tension only in T2D and with hyperlipidaemia only in 
(T1D).16 Diabetic maculopathy prevalence varies globally 
between 5.0% in combined Asian and 10.4% in African 
American populations,17 but whether associations with 
STDM are ethnicity specific and/or management depen-
dent remains unclear.12
We hypothesised routinely collected clinical risk factor 
data elements and not achieving clinical targets were 
associated with STDM among Indigenous Australians 
with T2D in a remote Indigenous primary healthcare 
setting. Therefore, our objectives were to identify associa-
tions between clinical risk factors (exposures) and STDM 
(outcome) in a primary care setting.
MATERIALS AND METHODS
Eligible primary care patients (Indigenous adults age ≥18 
years; n=301) with diagnosed T2D and at least 6 months 
of clinical data were recruited from a remote primary 
care service in Central Australia where the health service 
board approved researcher access to relevant electronic 
health record data for patients screened for DR between 
2014 and 2016, as previously published.11 The general 
primary care clinic was the only source of female partic-
ipants. Male patients sometimes preferred to attend a 
Men’s Clinic on a separate site nearby. Required exposure 
data from clinical records (current diabetes duration, 
HbA1c, blood pressure and lipid levels, anthropometric 
and renal function measures, insulin use and smoking 
status) were available for 281 adults in the retinopathy 
screened group, and 236 of these had both current 
clinical and gradable diabetic maculopathy data (‘partici-
pants’) for the maculopathy substudy (figure 1).
DR screening and treatment coverage, prevalence and 
vision findings have been reported elsewhere.11 Briefly, 
the DR screening protocol was as follows: Presenting 
vision, either unaided or aided, was recorded. Selective 
pupil dilation was used, that is, mydriatic eye drops (one 
each of 1% tropicamide and 2.5% phenylephrine) were 
instilled either by a clinician, certified imager, or by a 
non- clinical/inexperienced imager under clinical super-
vision, unless pupil diameter was adequate (≥4 mm), 
Figure 1 Flow diagram for participation in sight- threatening 
diabetic macular oedema (STDM) study.
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mydriatic drops were contraindicated or clinical supervi-
sion was unavailable. Five 45° retinal fundus fields and one 
anterior eye/external field per eye were imaged. Imaging 
studies were graded remotely by certified retinal graders 
in the Centre for Eye Research Australia at the Royal 
Victorian Eye and Ear Hospital in Melbourne. Type and 
number of retinal lesions were recorded and a grading 
algorithm provided a preliminary retinopathy and macu-
lopathy grade that could be modified by the grader who 
allocated a final ‘worse- eye’ grade. The grading report 
was uploaded to the electronic health record system 
of the remote health service. A clinician actioned the 
report based on the participant’s prior ocular history, 
for example, urgent referral to an ophthalmologist if no 
prior ‘referral to’ or ‘report from’ an ophthalmologist 
was present in the patient’s electronic health record.
Screening and action recommendations were based 
on the 2008 National Health and Medical Research 
Council of Australia Guidelines for the Management of 
Diabetic Retinopathy,18 in which the Early Treatment 
Diabetic Retinopathy Study classification ‘clinically- 
significant diabetic macular oedema’ (defined as any 
of the following characteristics: thickening of the retina 
at or within 500 µm of the centre of the macula; hard 
exudates at or within 500 µm of the centre of the macula, 
if associated with thickening of the adjacent retina (not 
residual hard exudates remaining after disappearance of 
retinal thickening); a zone or zones of retinal thickening 
one disc area or larger, any part of which is within one 
disc diameter of the centre of the macula is considered 
to be sight- threatening maculopathy, that is, STDM. The 
United Kingdom’s National Health Scheme Diabetic 
Eye Screening Programme grading equivalent would be 
Maculopathy level 1 (MI) plus some level of retinopathy 
(R1-3), for example, M1R2.19
Statistical analysis
Descriptive statistics and complete- case analysis were used 
to examine subgroups: demographic and clinical char-
acteristics of participants were compared using one- way 
analysis of variance for categorical independent variables 
and normally distributed dependent variables or non- 
parametric tests for non- normally distributed continuous 
dependent variables and χ2 tests for categorical variables. 
Participant clinical characteristics were summarised 
by sex (due to potential sex differences in the clin-
ical setting (men could attend the General or a Men’s 
Clinic (on a separate site) while all women attended 
the General Clinic), management and reported differ-
ences in clinical risk factors between Indigenous men 
and women nationally: for example, Indigenous women 
have a higher prevalence of diabetes and obesity, while 
smoking is more prevalent among Indigenous men) and 
by STDM status as mean (95% CI) or median (IQR) for 
continuous variables or percentages (counts) for categor-
ical data. A probability of p<0.05 was taken as statistically 
significant. Statistical analyses were conducted with IBM 
SPSS Statistics (V.25.0).
Patient and community involvement
This study was supported throughout by Indigenous 
community members and patients who were members 
on the board of the participating Indigenous health 
service. Other supporters were the study’s Indigenous 
liaison officer and Aboriginal Health Worker staff who 
assisted in modifying study protocols to minimise partic-
ipation time, facilitate recruitment, ensure development 
of culturally safe protocols and facilitate dissemination of 
the health information and study results as appropriate 
to family, friends and their community.
RESULTS
Of 281 individuals who had undergone retinal fundus 
imaging and had clinical risk factor data, 236 (78.4%) 
had images gradable for maculopathy (35.6% male). 
STDM study participant (n=236) and non- participant 
(n=45) characteristics were similar but for the older 
age of non- participants (57 (51–68) years), who had 
ungradable images primarily due to cataract, as reported 
previously.11 Participant characteristics were: median 
(IQR) age 48 (40–56) years, known diabetes duration 
8.0 (3.0–12.0) years, HbA1c 8.5 (6.8–10.4) %, (HbA1c 
69 (51–90) mmol/mol), systolic/diastolic blood pressure 
126/76 (115/70–140/82) mm Hg, low- density lipopro-
tein (LDL) cholesterol/high- density lipoprotein (HDL) 
cholesterol 2.3/1.0 (1.8/0.8–2.8/1.1) mmol/L, body 
mass index (BMI) 30.6 (26.3–35.3) kg/m2 and urinary 
albumin to creatinine ratio 5.1 (1.0–36.3) mg/mmol. 
Prevalence of STDM was 14.8% (n=35).
Participant characteristics by sex are reported in 
table 1. The proportion of men and women who had 
STDM, insulin prescribed, achieved lipid targets and 
normal eGFR was similar. On average, women had a 
higher HbA1c, but lower systolic and diastolic blood pres-
sure than men. A higher proportion of men than women 
were former or current smokers, hypertensive or albu-
minuric (elevated urinary albumin to creatinine ratio). 
Women were more likely to be anaemic, while men were 
more likely to have been prescribed statins.
The clinical profile of STDM (table 2) shows STDM 
was associated with longer known diabetes duration 
(figure 2), HbA1c above 9% (75 mmol/mol), lower BMI, 
severe macroalbuminuria, abnormal eGFR and chronic 
kidney disease. The STDM subset participants were less 
likely to be overweight or obese, and there was also a 
(non- significant) trend in the STDM group towards 
higher rates of anaemia and prescribed insulin (31.0% vs 
17.8%, p=0.094% and 31.4% vs 17.9%, p=0.065, respec-
tively).
DISCUSSION
To the best of our knowledge, this is the first study to 
describe the factors associated with STDM among Indige-
nous Australians in a remote primary- care setting. STDM 
prevalence was higher in both Indigenous men (13.1%) 
and women (15.8%) than reported in a recent national 
eye survey (6.0% Indigenous; 3.8% non- Indigenous),10 
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Table 1 Characteristics of participants, according to sex
Variables
















Age, years   48.8 46.3 51.4 47.9 46.0 49.8 0.562
Age at diabetes diagnosis, 
years
  40.9 38.4 43.4 38.4 36.6 40.3 0.112
Duration of diabetes, years   7.5 6.2 8.7 9.0 8.0 10.0 0.069
HbA1c, %   8.3 7.8 8.7 9.0 8.5 9.5 0.024
HbA1c, mmol/mol   67 62 72 75 69 80 0.024
Systolic BP*, mm Hg   130 119 150 124 113 136 0.003
Diastolic BP*, mm Hg   80 70 91 75 70 80 0.001
Total cholesterol, mmol/L   4.6 4.3 4.8 4.6 4.4 4.8 0.877
LDL- C, mmol/L   2.3 2.1 2.5 2.4 2.2 2.6 0.503
HDL- C, mmol/L   1.0 0.9 1.1 1.0 1.0 1.1 0.949
Triglycerides*, mmol/L   2.1 1.3 3.5 2.2 1.5 3.2 0.714
BMI, kg/m2   29.7 28.4 31.1 32.4 31.2 33.6 0.007
Haemoglobin, g/L Reference: men 130–180 g/L; women 
120–160 g/L
147.0 142.6 151.3 129.8 127.2 132.5 <0.001
Categorical variables Variable definitions Men (%) Women (%)
Newly diagnosed diabetes Defined as ‘known diabetes duration 
<1 year’
14.3 11.2 0.309
STDM present Clinically significant macular oedema 
(ETDRS definition)
13.1 15.8 0.361
Smoking status Never (reference level) 29.5 52.7 0.002
Former 24.4 12.8
Current 46.1 34.5
Albuminuria†   67.5 54.8 0.042









Severe macroalbuminuria (M and 
W>300 mg/mmol)
8.8 7.5
Normal eGFR eGFR ≥90, mLmin-1.73m2-1 63.4 55.0 0.233
Kidney function stage 1=eGFR≥90 (reference level) 63.4 55.0 0.531
2=eGFR 60–89 17.1 26.2
3=eGFR 44–59 4.9 4.7
4=eGFR 15–43 6.1 4.0
5=eGFR<15 8.5 10.1
Anaemia Haemoglobin level less than above 
reference ranges
11.7 23.8 0.022
HbA1c at target HbA1c≤7% (53 mmol/mol) 37.3 25.2 0.051
BP at target Systolic and diastolic BP at CARPA 
target
28.6 48.0 0.004
Systolic BP at target <130 mm Hg 42.9 61.8 0.005
Diastolic BP at target <80 mm Hg 42.9 62.5 0.004
Continued
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earlier Indigenous studies,11 and global data (7.4%).17 By 
contrast, the remarkably low STDM rate of 0.9% (n=394) 
among 46 853 Indigenous Americans screened by the 
Indian Health Service12 is noteworthy: In that cohort, 
STDM was associated with longer diabetes duration (as in 
this study), insulin use (a similar trend in this study), and 
a high HbA1c, that is, greater than 10% (86 mmol/mol) 
(greater than 9% (75 mmol/mol) in this study). While 
diabetic eye disease screening protocols differed between 
some of these studies, all protocols had adequate sensi-
tivity for the detection of treatable diabetic maculopathy, 
that is, clinically- significant diabetic macular oedema 
(STDM), and it is unlikely the reported prevalence 
differences can be attributed to heterogeneous screening 
protocols.
Implications of diabetes duration in primary care practice
Our findings suggest that among Indigenous Australians, 
diabetes duration may be a useful risk marker for STDM, 
the most common cause of impaired vision and blind-
ness in diabetic populations and an important predictor 
of other complications and all- cause mortality.20 Diabetes 
duration also predicts non- referable DR, which can now 
be treated medically with fenofibrate in Australians with 
T2D and existent retinopathy, independent of lipid 
levels, by primary care doctors or nurse practitioners with 
prescribing rights. Fenofibrate has also been approved 
for use to retard DR progression in T2D in 18 other coun-
tries (personal communication Abbott).
Until a validated Indigenous risk calculator for 
DR becomes available, an interim, simple and effec-
tive primary care risk management strategy worth 
consideration might be to triage those individuals with 
a known diabetes duration of over 10 years to more 
frequent comprehensive eye exams or camera- based DR 
screening where barriers to regular comprehensive eye 
exams exist. This strategy is supported by the findings 
in the 2016 National Eye Health Survey21 that reported 
only 53% of Indigenous Australians with diabetes are 
screened according to current evidence- based recom-
mendations in Australia’s Clinical Guidelines for the 
Management of Diabetic Retinopathy.18 By contrast, 
screening coverage of non- Indigenous Australians in the 
2016 survey was 78%, and this difference in screening 
coverage may in part explain the lower blindness rate 
among non- Indigenous than Indigenous Australians. 
Importantly, treatment coverage in our study group was 
similar to national treatment coverage data for both 
Indigenous and non- Indigenous Australians, as reported 
previously.11 It is noteworthy that national screening 
recommendations have been unchanged for more than 
20 years, that is, since 1997 when diabetic eye disease was 
declared a major public health problem by the Australian 
government.
Implications for primary care practice of age at diabetes 
diagnosis and established risk factors
The relatively younger age at diagnosis of diabetes among 
Indigenous than non- Indigenous Australians and the 
increasing life expectancy of Indigenous Australians may 
in part explain the higher prevalence of STDM observed 
among Indigenous Australians with diabetes in recent 
studies.10 11 Since most participants with STDM (78%) 
had already been treated for STDM, intensified primary 
Variables
















BMI category Not overweight/obese 23.8 14.9 0.013
Overweight 32.5 24.3
Obese (BMI 30<35) 36.3 46.6
Morbidly obese 7.5 14.2
Total cholesterol at target   31.6 29.1 0.685
LDL- C at target   57.9 60.00 0.762
HDL- C at target   53.1 56.40 0.632
Triglycerides at target   28.4 26.20 0.717
UACR elevated ≥2.5 men; ≥3.5 women 67.5 54.80 0.042
Insulin prescribed   16.7 21.70 0.353
Statin prescribed   81.6 70.30 0.048
Known CVD   33.3 25.70 0.211
*Data are median and IQR.
†All definitions and targets for Indigenous adults with diabetes as defined in the Central Australian Rural Practitioner‘s Association 
(CARPA) standard treatment manual (seventh edition).
BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; ETDRS, Early Treatment Diabetic Retinopathy Study; STDM, 
sight- threatening diabetic maculopathy; UACR, urinary albumin to creatinine ratio.
Table 1 Continued
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Continuous Lower Upper Lower Upper
Age*, years   47.0 39.0 56.0 49.0 43.0 56.0 0.398
Age at diabetes 
diagnosis, years
  39.6 38.0 41.3 37.4 34.3 40.5 0.281
Duration of diabetes, 
years
  7.9 7.1 8.8 11.7 9.8 13.5 <0.001
HbA1c, %   8.7 8.3 9.1 9.1 8.4 9.9 0.374
HbA1c, mmol/mol   72 67 76 76 68 85 0.374
Systolic BP*, mm Hg   125 115 139 130 120 156 0.138
Diastolic BP, mm Hg   77 76 79 74 70 79 0.152
Total cholesterol, mmol/L   4.5 4.4 4.7 4.9 4.4 5.4 0.148
LDL- C*, mmol/L   2.3 1.8 2.7 2.3 1.9 3.3 0.692
HDL- C, mmol/L   1.0 1.0 1.1 1.0 0.9 1.2 0.667
Triglycerides, mmol/L   2.6 2.3 2.9 2.9 2.3 3.5 0.471
BMI, kg/m2   31.9 30.9 32.9 28.9 26.7 31.1 0.020
Haemoglobin, g/L   137 134 139 130 123 137 0.078
Categorical†† Variable definitions STDM absent (%) STDM present (%)
Newly diagnosed 
diabetes
  13.4 5.7 0.199
Female sex   63.7 68.6 0.577
Smoking status Never (reference level) 43.5 51.5 0.693
Former 17.1 15.2
Current 39.4 33.3
Albuminuria†   59.4 58.8 0.952










(M and W>300 mg/mmol)
5.7 20.6
Normal eGFR eGFR ≥90, mLmin-11.73m2-1 61.7 37.1 0.007
Kidney function stage 1=eGFR≥90 (reference level) 61.7 37.1 0.054
2=eGFR 60–89 21.4 31.4
3=eGFR 45–59 4.6 5.7
4=eGFR 15–44 4.6 5.7
5=eGFR<15 7.7 20.0
CKD present CARPA definition 12.2 25.7 0.035
Anaemia present Haemoglobin level lower than sex- specific 
reference range
17.8 31.0 0.094
HbA1c at target HbA1c ≤7% (53 mmol/mol) 31.2 20.0 0.182
BP at target Systolic and diastolic BP at CARPA target 41.8 37.1 0.374
Systolic BP at target (<130 mm Hg) 57.2 42.9 0.082
Diastolic BP at target (<80 mm Hg) 53.7 65.7 0.128
Continued
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care risk factor management post- STDM treatment may 
in part explain the lack of an association between STDM 
and some known modifiable retinopathy risk factors, 
such as HbA1c, blood pressure and lipids.
Elevated blood pressure is a risk factor for DR and 
maculopathy globally,15 22 23 but in this clinical population 
was not associated with STDM. As in most clinical popula-
tions with diabetes, HbA1c levels were suboptimal in this 
clinical population. However, the anticipated difference 
in HbA1c level between those with and without STDM 
was not observed, most likely due to the high STDM treat-
ment coverage and post- treatment intensified glycaemic 
control in this setting, that is, the proportion with 
untreated STDM was 22%.
Given the prevalence of diabetes is almost sevenfold 
higher in Indigenous than non- Indigenous Australians 
in the 24–35 year age group and fourfold higher overall,3 
these data suggest a need for intensified management 
of blood pressure and blood glucose levels in younger 
Indigenous Australians with diabetes.
We observed a non- statistical trend towards greater 
prescribed insulin in those with versus without STDM. 
Insulin use in T2D usually reflects longer diabetes dura-
tion, more advanced progression of the natural history 
of T2D with beta- cell failure, and of prior poor glycaemic 
control. Adherence to prescribed medications was not 
recorded routinely in clinical records, nor is linkage 
with pharmacy prescription dispensing data available in 
Australia. Therefore, it is possible that some medication 
usage misclassification may have occurred and reduced 
our ability to detect an association of for example, 
prescribed insulin with STDM.
The association between DR and nephropathy is 
well- known, and both are frequently asymptomatic. 
Therefore, detection in primary care of either renal 
or retinal disease in a person with diabetes flags the 
need to urgently screen for the other, and the urinary 
albumin to creatinine ratio, an important biomarker for 
microalbuminuria, and also plasma creatinine can now 
be performed as point- of- care pathology tests, ideal for 
remote healthcare services.24 25 Our findings also present 
a rationale for considering future diabetes eye screening 
studies of Indigenous Australians in renal clinics and 
dialysis centres, in addition to primary care settings, as 










Continuous Lower Upper Lower Upper
BMI status Not overweight/obese 14.5 37.1 0.012
Overweight (BMI 25–29.9 kg/m2) 28.5 20.0
Obese (BMI 30–34.9 kg/m2) 44.0 37.1
Morbidly obese (BMI 35 kg/m2or higher) 13.0 5.7
Total cholesterol at target   31.6 20.6 0.137
LDL- C at target   60.1 54.5 0.339
HDL- C at target   55.4 54.3 0.524
Triglycerides at target   26.7 28.6 0.480
UACR at target <2.5 men; <3.5 women 40.6 41.2 0.548
Insulin prescribed   17.9 31.4 0.065
Statin prescribed   74.2 75.0 0.922
Known CVD   27.9 31.4 0.666
*Data are median and IQR.
†All definitions and targets for Indigenous adults with diabetes as defined in the Central Australian Rural Practitioner‘s Association (CARPA) standard 
treatment manual (seventh edition).
BMI, body mass index; BP, blood pressure; CKD, chronic kidney disease; CVD, cardiovascular disease; ETDRS, Early Treatment Diabetic 
Retinopathy Study; STDM, sight- threatening diabetic maculopathy (defined as ETDRS clinically significant diabetic macular oedema); UACR, urinary 
albumin to creatinine ratio.
Table 2 Continued
Figure 2 Sight- threatening diabetic macular oedema 
(STDM) (%) by duration of diabetes categories.
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important insights into the observed STDM- renal associ-
ation.
Obesity is a risk factor for the chronic complications of 
diabetes, including DR,22 yet we identified a novel inverse 
association between STDM and BMI. This may be due to 
unmeasured confounding, such as comorbid conditions, 
progressive beta cell failure with increasing duration 
of diabetes, or may reflect the need for caution in the 
standard interpretation of BMI that was developed as a 
measure of healthy weight in and for
Caucasian populations that have different body 
proportions to the Indigenous Australian population.26 27 
A BMI cut- off of 22 kg/m2 has been suggested to define 
the upper limit of the healthy weight range for Indige-
nous Australians. Based on this cut- off, the proportion 
of participants in the non- overweight/obese range falls 
from 37.1% to 11.4% and the association between BMI 
status and STDM becomes statistically non- significant 
(p=0.157).
To date, risk management of diabetic eye disease 
in primary care has been based on treatment of estab-
lished retinopathy risk factors (prevention), regular 
eye exams or camera- based retinopathy screening 
(early detection of disease), intensified treatment of 
risk factors (management of prevalent non- sight threat-
ening disease) and referral of sight- threatening disease 
for tertiary treatment. More recently, DR risk calculators 
have been developed,28 29 but none are based on Indig-
enous eye data or specifically address risk of STDM, the 
most common cause of vision loss in diabetes. This is an 
important knowledge gap in Indigenous and eye health 
research. Until such a tool is developed, our findings 
together with current risk management approaches 
suggest strategies that may help address STDM risk in 
this setting, including risk stratification by diabetes dura-
tion; intensified management of risk factors associated 
with STDM, particularly in the younger diabetes- onset 
group, and primarily systolic hypertension and renal 
dysfunction. Furthermore, our findings strongly support 
an integrated telemedicine retinal screening programme 
in primary care services and/or community settings 
to augment existing ophthalmic services and address 
low screening coverage of Indigenous Australians with 
diabetes. Improved screening rates would not only iden-
tify people with or at high risk of STDM and related 
diabetes complications, but may alert clinicians when 
intensified management is needed to prevent STDM and 
related adverse outcomes. For example, formation of 
two or more microaneurysms between successive annual 
retinal screenings is a predictive marker for progression 
to STDM within 5 years.30 The importance of STDM 
extends well beyond the increased risk of vision loss and 
blindness, which is in itself a great individual, societal and 
public health burden. People with diabetic maculopathy 
are also at increased risk of incident CVD7 and premature 
mortality and so should be followed more closely and 
their risk factors aggressively treated.
We acknowledge both study strengths and limitations: 
importantly, this is the first study to examine STDM, the 
main cause of vision loss in diabetes globally, among 
Indigenous Australians. Furthermore, we shed light on 
modifiable clinical factors associated with the dispro-
portionately high and increasing prevalence of STDM 
among Indigenous Australians with diabetes. We expect 
these findings to influence care provision of any person 
with diabetes who has any markers of renal dysfunction 
or duration of diabetes of at least 10 years by raising the 
treating doctor’s index of suspicion for STDM and aware-
ness of the need for more frequent retinal screening. 
Importantly, the infrastructure and training for image- 
based diabetic eye screening in Indigenous primary 
care clinics has been largely funded by the Australian 
Government, and the screening is a reimbursable service 
under the national Medicare Health Benefits Scheme. 
Consequently, the clinical and cost effectiveness of the 
retinal screening model has already been established, 
and the granularity our findings provide will improve risk 
management of sight- threatening diabetic eye disease 
and lead to earlier detection and timelier treatment, 
thereby further improving clinical and cost effectiveness 
of this screening model.
However, the following limitations are noteworthy: 
there may be selection bias as some people with (known 
or unknown) T2D may not have attended a primary 
care clinic. Site differences may have contributed to the 
sex- specific associations with STDM, since male partic-
ipants may have attended the Men’s Clinic rather than 
the General Clinic attended by female and male partic-
ipants. However, unlike non- Indigenous studies where 
participation rates are similar by sex, Indigenous male 
participation rates are generally lower than Indigenous 
female participation rates in retinopathy screening 
studies. Causal inferences cannot be made given the 
cross- sectional nature of the data, that is, risk factor levels 
(eg, BMI, BP, HbA1c, levels, Albumin to Creatinine Ratio 
(ACR)) are reported at the time of assessment and not 
over time. T2D may be present for years prior to its formal 
diagnosis; hence, diabetes duration may be an underesti-
mate. There may be measurement error in some clinical 
risk factors such as weight and blood pressure obtained by 
clinic staff. They were not verified by research staff. Due 
to the number with STDM, multivariate analysis was not 
undertaken. Similarly, the untreated STDM subset was 
too small to undertake subanalyses to compare clinical 
associations between treated and untreated STDM cases. 
Larger Indigenous STDM studies are needed to better 
understand the factors associated with STDM and the 
impact of STDM treatment on risk factor control, given 
the important association reported recently between 
diabetic eye disease and 10- year mortality in a remote 
Indigenous population.31
Finally, remoteness is a risk factor for other adverse 
health outcomes in Australia, notably diabetes,31 and 
may have been a contributing factor to the observed 
associations with STDM. However, our findings have face 
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validity as they are broadly in line with current evidence. 
Moreover, our sample is representative of the Indigenous 
Australian population with diabetes on key parameters, 
such as prevalence of diabetes and risk factors for DR, 
and so we expect our findings to be generalisable to 
the Indigenous sector of the Australian population with 
diabetes.
The factors underpinning both the apparent suscepti-
bility of remote- living Indigenous Australians to STDM 
and the different clinical profiles in Indigenous men and 
women, despite similarly high STDM prevalence rates, 
require further evaluation. Future Indigenous studies of 
diabetic maculopathy should include earlier (non- sight- 
threatening) stages of maculopathy as an outcome, now 
detectable with optical coherence tomography technology, 
and a broader range of exposures among Indigenous 
Australians in larger multicentre Australian studies that 
include urban, regional and very remote primary care 
settings. Given the high rates of STDM and blindness 
among Indigenous Australians and the approved use 
in Australia of fenofibrate for slowing retinopathy and 
maculopathy progression to sight- threatening stages and 
tertiary intervention,14 32 a fenofibrate intervention arm 
in future Indigenous primary care studies of diabetic eye 
diseases may be warranted. Fenofibrate can also slow the 
progression of renal dysfunction,14 33 which has recently 
been associated with 10- year mortality in this remote 
population.31 For successful implementation and effec-
tive outcomes of such studies and interventions, local 
Indigenous community support, culturally- sensitive 
protocols and collaboration with ophthalmic clinicians, 
ideally local, are essential.
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